title: Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry.
abstract: We report a retrospective analysis of 53 haematopoietic stem cell transplants for inherited metabolic disorders performed at ANZCHOG transplant centres between 1992 and 2008. Indications for transplant included Hurler syndrome, ALD, and MLD. The majority of transplants utilized unrelated donor stem cells (66%) with 65% of those being unrelated cord blood. Conditioning therapy was largely myeloablative, with Bu plus another cytotoxic agent used in 89% of recipients. Primary graft failure was rare, occurring in three patients, all of whom remain long-term survivors following the second transplant. The CI of grade II-IV and grade III-IV acute GVHD at day +100 was 39% and 14%, respectively. Chronic GVHD occurred in 17% of recipients. TRM was 12% at day +100 and 19% at one yr post-transplant. OS at five yr was 78% for the cohort, 73% for patients with ALD and 83% for patients with Hurler syndrome. There was no statistically significant difference in overall survival between unrelated marrow and unrelated cord blood donor groups. The development of interstitial pneumonitis was an independent variable shown to significantly impact on TRM and OS. In summary, we report a large cohort of patients with inherited metabolic disorders with excellent survival post-allogeneic transplant.
authors.affiliation: Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, Randwick, NSW, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Mitchell
authors.forename: I
authors.initials: I
authors.lastname: Nivison-Smith
authors.forename: A
authors.initials: A
authors.lastname: Anazodo
authors.forename: K
authors.initials: K
authors.lastname: Tiedemann
authors.forename: P J
authors.initials: PJ
authors.lastname: Shaw
authors.forename: L
authors.initials: L
authors.lastname: Teague
authors.forename: C J
authors.initials: CJ
authors.lastname: Fraser
authors.forename: T L
authors.initials: TL
authors.lastname: Carter
authors.forename: H
authors.initials: H
authors.lastname: Tapp
authors.forename: F
authors.initials: F
authors.lastname: Alvaro
authors.forename: T A
authors.initials: TA
authors.lastname: O'Brien
mesh_terms: D000326:Adrenoleukodystrophy / Q000628:therapy; D001315:Australia; D016026:Bone Marrow Transplantation / Q000379:methods*; D015331:Cohort Studies; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007966:Leukodystrophy, Metachromatic / Q000628:therapy; D008297:Male; D008661:Metabolism, Inborn Errors / Q000628:therapy*; D008059:Mucopolysaccharidosis I / Q000628:therapy; D015999:Multivariate Analysis; D009520:New Zealand; D012042:Registries; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
keywords: Hurler syndrome; adrenoleucodystrophy; bone marrow transplantation